Dr. Lin Römer
pharmafile | January 31, 2023 | Appointment | Business Services |
Munich, 31 January 2023 – Insempra, a biology-powered company enabling businesses to make superior products in partnership with nature, today announces the appointment of Dr. Lin Römer as Chief Operating Officer. Lin will join Jens Klein, CEO and Founder, and Andreas Heyl, CTO in the Insempra management team, effective January 2023.
Lin Römer comes with extensive experience in corporate strategy, product development and successfully scaling biotech products. In his role, Lin will orchestrate and streamline key resources for the successful development and launch of Insempra’s innovative products and play a key role in driving operational excellence, as well as accelerating the company’s growth strategy.
“Insempra is in a very strong position in the emerging field of sustainable biotech products,” Lin comments. “This new position allows me to continue my focus on bringing innovative biotech products to market, whilst accelerating Insempra’s goals and expansion into new areas and markets. I am excited to be supporting Insempra drive the regenerative revolution.”
Prior to joining Insempra, Lin served as co-founder and CTO of AMSilk GmbH, the world’s first industrial supplier of vegan silk biopolymers. In this position Lin was instrumental in scaling AMSilk’s products from the lab to an industrial scale, resulting in the successful market launches of the world’s first artificial spider silk products.
“Lin joins Insempra at exactly the right time, as we are growing fast – and innovating even faster,” comments Jens Klein, CEO and Founder of Insempra. “Our focus is on ensuring that our growth is managed efficiently as we target multiple industries with our innovative product portfolio. Lin has a proven track record which will be invaluable to Insempra as we move into this next significant phase of growth.”
